Patents Assigned to Thrombotech Ltd.
  • Peptides for regulation of urokinase (uPA) and tissue type (tPA) plasminogen activator and method of optimizing therapeutic efficacy
    Patent number: 7271143
    Abstract: Compositions of the polypeptide SEQ ID NO:1, SEQ ID NO:2, anti-LRP antibodies, LRP antagonists, and/or one or more fibrinolytic agents are formulated for enhancing the fibrinolytic activity, reducing the side effects due to vasoactivity caused by the fibrinolytic agents, and/or prolonging the half lives of the fibrinolytic agents. The invention further relates to combination compositions and/or therapy regimens, comprising the polypeptide SEQ ID NO:1 and/or SEQ ID NO:2 and one or more currently used plasminogen activators.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: September 18, 2007
    Assignee: Thrombotech Ltd.
    Inventor: Abd. Al-Roof Higazi
  • Medical uses of scuPA/suPAR complex
    Patent number: 6911316
    Abstract: Methods of using a complex (scuPA/suPAR) which has thrombolytic activity under physiological conditions and in the presence of IgG, or of at least one IgG-derived peptide, which complex comprises a single chain urokinase type plasminogen activator (scuPA) and a soluble urokinase plasminogen activator receptor (suPAR), for the treatment and/or prevention of thromboembolic disorders associated with the formation of fibrin clots are disclosed.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: June 28, 2005
    Assignee: Thrombotech Ltd.
    Inventor: Abd Al-Roof Higazi